Anti-candidal activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of Candida albicans

Medical Mycology

Volumn 50, Issue 1, 2012, Pages 33-42

  Khan, Mohd Sajjad Ahmad ^a   Malik, Abida ^b   Ahmad, Iqbal ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

amphotericin B; Candida albicans; drug resistance; essential oils; fluconazole; synergy

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; APIUM GRAVEOLENS EXTRACT; CINNAMALDEHYDE; CINNAMOMUM VERUM EXTRACT; CITRAL; CITRUS LIMON EXTRACT; CITRUS PARADISI EXTRACT; CYMBOPOGON CITRATUS EXTRACT; CYMBOPOGON MARTINI EXTRACT; EUGENOL; FLUCONAZOLE; FOENICULUM VULGARE EXTRACT; GINGER EXTRACT; ITRACONAZOLE; KETOCONAZOLE; MYRISTICA FRAGRANS EXTRACT; PEPPERMINT; PETROSELINUM CRISPUM EXTRACT; PLANT EXTRACT; ROSEMARINUS OFFICINALIS EXTRACT; SANTALUM ALBUM EXTRACT; SYZYGIUM AROMATICUM EXTRACT; UNCLASSIFIED DRUG; ZEA MAYS EXTRACT;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CELERIAC; CINNAMOMUM VERUM; CINNAMON; CLOVE; CONTROLLED STUDY; CYMBOPOGON CITRATUS; CYMBOPOGON MARTINI; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; FENNEL; GINGER; GRAPEFRUIT; LEMON; MAIZE; MEDICINAL PLANT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUTMEG; PARSLEY; ROSEMARINUS OFFICINALIS; SANTALUM ALBUM;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CYMBOPOGON; DRUG RESISTANCE, MULTIPLE, FUNGAL; DRUG SYNERGISM; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; OILS, VOLATILE;

EID: 83755164273     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.582890     Document Type: Article

References (36)

1. Aperis G, Myriounis N, Spanakis EK, Mylonakis E. Developments in the treatment of candidiasis: more choices and new challenges. Expert Opin Investig Drugs 2006; 15: 1319-1336. (Pubitemid 44615283)
2. De Repentigny L, Lewandowski D, Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodefi ciency virus infection. Clin Microbiol Rev 2004; 17: 729-759. (Pubitemid 39372514)
3. Davies AN, Brailsford SR, Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncol 2006; 42: 698-702. (Pubitemid 44094236)
4. Groll AH, Kolve H. Antifungal agents:in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 2004; 23: 256-270. (Pubitemid 38669937)
5. Herbrecht R, Natarajan-Ame S, Nivoix Y, Letscher-Bru V. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003; 4: 1277-1287. (Pubitemid 36949676)
6. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: Current epidemiological trends. Clin Infect Dis 2006; 43: S3-S14. (Pubitemid 44078892)
7. Sobel JD, Zervos M, Reed BD, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: Clinical implications. Antimicrob Agents Chemother 2003; 47: 34-38. (Pubitemid 36070338)
8. Revankar SG, Kirkpatrick WR, McAtee RK. e t al. Detection and signifi cance of fl uconazole resistance in oropharangeal candidiasis in human immunodefi ciency virus infected patients. J Infect Dis 1996; 174: 821-827.
9. Perea S, Lopez-Ribot JL, Wickes BL, et al. Molecular mechanisms of fl uconazole resistance in Candida dubliniensis isolates from human immunodefi ciency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002; 46: 1695-1703. (Pubitemid 34535185)
10. De Logu A, Saddi M, Cardia MC, e t al. In vitro activity of 2- cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fl uconazole against clinical isolates of Candida spp. and fl uconazole-resistant Candida albicans. J Antimicrob Chemother 2005; 55: 692-698. (Pubitemid 40691848)
11. Messer SA, Diekema DJ, Boyken L, e t al. Activities of micafungin against 315 invasive clinical isolates of fl uconazole-resistant Candida spp. J Clin Microbiol 2006; 44: 324-326. (Pubitemid 43222217)
12. Onyewu C, Heitman J. Unique applications of novel antifungal drug combinations. Anti-infect Agents Med Chem 2007; 6: 3-15. (Pubitemid 46062411)
13. Ahmad I, Khan MSA, Zahin M, e t al. Combinational antifungal therapy and recent trends in drug discovery. In: Ahmad I, Owais M, Shahid M, Aqil F (eds). Combating Fungal Infections: Problems and Remedy 1st edn. Berlin Heidelberg: Springer-Verlag, 2010: 213-240.
14. Mondello F, De Bernardis F, Girolamo A, Cassone A, Salvatore G. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species. BMC Infect Dis 2006; 6: 158-165.
15. Noumi E, Snoussi M, Hajlaoui H, Valentin E, Bakhrouf A. Antifungal properties of Salvadora persica and Juglans regia L. extracts against oral Candida strains. Eur J Clin Microbiol Infect Dis 2010; 29: 81-8.
16. Zhang JD, Xu Z, Cao YB, e t al. Antifungal activities and action mechanisms of compounds from Tribulus terrestris L. J Ethnopharmacol 2006; 103: 76-84. (Pubitemid 41681145)
17. Khodavandi A, Alizadeh F, Aala F, Sekawi Z, Chong PP. In vitro investigation of antifungal activity of allicin alone and in combination with azoles against Candida species. Mycopathologia 2010; 169: 287-295.
18. Mahboubi M, Bidgoli FG. In vitro synergistic effi cacy of combination of amphotericin B with Myrtus communis essential oil against clinical isolates of Candida albicans. Phytomedicine 2010; 17: 771-774.
19. Clinical and Laboratory Standards Institute. R eference Method for Antifungal Disc Diffusion Susceptibility Testing of Yeasts. Proposed guideline M44-A2, Wayne, PA: Clinical and Laboratory Standards Institute USA, 2009.
20. Sokovic M, Van Griensven LJLD. Antimicrobial activity of essential oils and their components against the three major pathogens of the cultivated button mushroom, Agaricus bisporus. Eur J Plant Pathol 2006; 116: 211-224. (Pubitemid 44526872)
21. Clinical and Laboratory Standards Institute. R eference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Proposed guideline M27-A3, Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
22. Colombo AL, Barchiesel F, McGough DA, Rinaldi MG. Comparison of Etest and national committee for clinical laboratory standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 1995; 33: 535-540.
23. Vitale RG, Afeltra J, Dannoui E. Antifungal combinations. In: Ernst EJ, Rogers PD (eds). Antifungal Agents: Methods and Protocols Totowa, NJ: Humana Press Inc, 2005: 143-152.
24. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1. (Pubitemid 36850074)
25. Yang YL, Li SY, Cheng HH, Lo HJ, TSARY Hospitals. The trend of susceptibilities to amphotericin B and fl uconazole of Candida species from 1999 to 2002 in Taiwan. BMC Infect Dis 2005; 5: 99-103.
26. Milan EP, Burattini MN, Kallas EG, et al. Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure. Diagn Microbiol Infect Dis 1998; 32: 211-216. (Pubitemid 29017741)
27. Swinne D, Watelle M, Nolard N. In vitro activities of voriconazole, fl uconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22: 24-28. (Pubitemid 40675571)
28. Hamza OJM, Matee MIN, Moshi MJ, et al. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol 2008; 8: 135-143.
29. Tseng YH, Lee WT, Kuo TC. In-vitro susceptibility of fl uconazole and amphotericin B against Candida isolates from women with vaginal candidiasis in Taiwan. J Food Drug Anal 2005; 13: 12-16.
30. Thakur JK, Arthanari H, Yang F, e t al. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008; 452: 604-609. (Pubitemid 351483364)
31. Khan MSA, Ahmad I. Antifungal activity of essential oils and their synergy with fl uconazole against drug-resistant strains of Aspergillus fumigatus and Trichophyton rubrum. Appl Microbiol Biotechnol 2011; 90: 1083-1094.
32. Vazquez JA. Combination antifungal therapy against C andida species: the new frontier - are we there yet? Med Mycol 2003; 41: 355-368. (Pubitemid 37441439)
33. Ishida K, De Mello JCP, Cortez DAG, et al. Infl uence of tannins from Stryphnodendron adstringens on growth and virulence factors of Candida albicans. J Antimicrob Chemother 2006; 58: 942-949.
34. Pinto E, Pina-Vaz C, Salgueiro L, et al. Antifungal activity of the essential oil of Thymus pulegioides on Candida Aspergillus and dermatophyte species. J Med Microbiol 2006; 55: 1367-1373. (Pubitemid 44651663)
35. Rautemaa R, Richardson M, Pfaller M, Perheentupa J, Saxen H. Reduction of fl uconazole susceptibility of Candida albi ca ns in APECED patients due to long-term use of ketoconazole and miconazole. Scand J Infect Dis 2008; 40: 904-907.
36. Pinto PM, Weikert-Oliveira RC, Lyon JP, et al. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis. Microbiol Res 2008; 163: 579-585.